Navigation Links
Alliance for Biosecurity Testifies Before Congress on Funding for Medical Countermeasure Development

WASHINGTON, March 18 /PRNewswire-USNewswire/ -- David P. Wright, Co-Chair of the Alliance for Biosecurity and Chairman and CEO of PharmAthene, Inc., testified today before the House Labor, Health and Human Services, and Education Appropriations Subcommittee on the critical importance of developing drugs, vaccines and other medical countermeasures needed to protect Americans from bioterrorism and other catastrophic health emergencies. Effective medical countermeasures for many of the chemical, biological, radiological, and nuclear (CBRN) agents that pose the greatest threat to the United States do not currently exist, and Wright argued that the federal government should take a more active role in supporting their development to bolster the nation's biosecurity.

"Protecting our nation against bioterror threats is no less important than ensuring that we have the tools necessary to fortify and protect our military," Wright noted, but "funding for the development of CBRN countermeasures, particularly in the area of advanced development, has been woefully inadequate." Wright stated that "without adequate funding, promising countermeasures will not be developed and the nation will remain vulnerable to a bioterror attack - and make no mistake, a bioterror attack is a real and credible threat."

New drug development is an extraordinarily time consuming and resource-intensive process that requires 10-15 years and approximately $800 million from start to finish for one product. To help accelerate the development of needed medical countermeasures, the Alliance recommended that Congress provide $1.7 billion in FY 2010 to support the advanced research and development of biodefense countermeasures. The principle agency responsible for these activities is the Biomedical Advanced Research and Development Authority (BARDA) within HHS. Wright observed that when Congress created BARDA in 2006 it authorized $1.07 billion specifically for this purpose, but to date it has provided less than half of this amount. Wright highlighted several promising vaccines and therapies that could benefit from increased funding and noted that each new biotech job results in the creation of 5.8 additional jobs in other industries. "Increased funding would advance the day when our nation has access to these critical countermeasures," Wright stated, but "until that day arrives, the American people remain at risk."

About the Alliance for Biosecurity

The Alliance for Biosecurity was formed in June of 2005 by biopharmaceutical companies and the Center for Biosecurity of the University of Pittsburgh Medical Center. Alliance members are committed to partnering with government and promoting a new era in the prevention and treatment of severe infectious diseases - particularly those that present global security challenges - through innovative and accelerated research, development and production of countermeasures. Company members of the Alliance include: Bavarian-Nordic, Cangene Corporation, DOR BioPharma, Inc., Dynport Vaccine Company LLC, a CSC Company, Elusys Therapeutics, Emergent BioSolutions, Hematech, Inc., a subsidiary of Kyowa Kirin, Human Genome Sciences, Inc., NanoViricides, Inc., Pfizer Inc., PharmAthene, Siga Technologies, and Unither Virology LLC, a subsidiary of United Therapeutics.

SOURCE Alliance for Biosecurity
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
2. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
3. Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Progeniq Joins Microsoft in Bio IT Alliance
6. Campbell Alliance Managed Markets Practice to Take Leadership Role at CBIs Formulary and Reimbursement Conference
7. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
8. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
9. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
10. Campbell Alliance Named Best Place to Work by Triangle Business Journal
11. Campbell Alliance Business Development Practice to Moderate Two Workshops at LES Annual Meeting in Vancouver
Post Your Comments:
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
(Date:11/25/2015)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... discussion at the Piper Jaffray 27th Annual Healthcare Conference ... is scheduled for Wednesday, December 2, at 8:00 a.m. ... will be available for 14 days after the event.  ... Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
Breaking Biology Technology:
(Date:11/11/2015)... 2015   MedNet Solutions , an innovative SaaS-based eClinical ... is pleased to announce that it will be a Sponsor ... event, to be held November 17-19 in Hamburg ... demonstrations of iMedNet , MedNet,s easy-to-use, proven ... has been able to deliver time and cost savings ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/9/2015)... Calif. , Nov. 9, 2015  Synaptics Inc. ... interface solutions, today announced broader entry into the automotive ... solutions that match the pace of consumer electronics human ... biometric sensors are ideal for the automotive industry and ... Europe , ...
Breaking Biology News(10 mins):